Spdr S&P Biotech Etf (XBI) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Spdr S&P Biotech Etf (XBI)

159.03

-5.25 (3.20%)

as of Jul 10, 2026, 8:00:00 pm Market Open.

24 watching

Investor Insights

Jul 10, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

The Spdr S&P Biotech ETF (XBI) has elicited mixed opinions among experts, reflecting recent shifts in the biotech sector. Some reviews indicate that the ETF is experiencing a revival after a prolonged period of underperformance, particularly since mid-2023, with signs of significant growth potential due to factors such as advancements in AI accelerating drug discovery. Others caution that volatility persists, though the equal weight methodology of XBI aims to mitigate this risk. Several experts suggest that while the ETF's recent rally is promising, concerns around Fed policies and potential oversupply in the market could present short-term challenges. Overall, the sentiment seems cautiously optimistic about the ETF's future, particularly as biotech appears to be gaining momentum again, offering a diversified way to capture sector growth.

Consensus

Positive

Valuation

Fair Value

Similar

IBB

SELL ON STRENGTH

Exposure to the covid vaccine is quite minimal in this ETF. Very short term over-bought and he expects a 10-15% correction. Trim some exposure into strength. Longer term, the biotech sector looks good.

BUY

The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

PAST TOP PICK

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.

TOP PICK

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

COMMENT

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

BUY

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

Showing 16 to 21 of 21 entries

Most Recent Experts

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Spdr S&P Biotech Etf (XBI)